摘要
目的观察米非司酮与米索前列醇治疗子宫内膜不典型增生的疗效和安全性。方法治疗组:米非司酮150mg,口服,1次/3d;米索前列醇0.6mg,口服,米非司酮服用后48h服用一次;6d一个周期。对照组:甲羟孕酮30mg,口服,1次/d,6d一个周期,12个周期后对效果进行评价。结果治疗组患者20例完成12个周期的治疗,10例结果为显效,8例有效,2例无效,无恶化者。治疗组评价总有效率90%(18/20)。对照组患者20例完成12个周期的治疗,8例病理结果为显效,4例有效,8例无效,无恶化者。治疗组评价总有效率60%(12/20),差异有统计学意义(P<0.05)。结论米非司酮与米索前列醇联合治疗子宫内膜不典型增生有效率高,疗效、减少毒副反应方面均优于甲羟孕酮,具有较好的安全性和临床疗效,可作为子宫内膜不典型增生治疗的首选方案之一。
Objective To observe the efficacy and safety of endometrial atypical hyperplasia by Mifepristone and Misoprostol.Methods Treatment group：Mifepristone 150 mg,orally,take it once per three days;Misoprostol 0.6 mg,orally,take it once after taking Mifepristone about 48 hours;Six days per cycle.The control group：Provera（DMPA）30 mg,orally,once a day,six days per cycle,and evaluate the effects after 12 cycles.Results 20 patients in treatment group completed 12 cycles of chemotherapy,10 cases pathology results for powerfully,8 cases of effective,2 cases of invalid,without the deterioration.The total effective rate in treatment group evaluation was 90%（18/20）.20 cases of patients with complete control 12 cycles of treatment,8 cases of pathological results for powerfully,4 cases effective,8 cases of invalid,without the deterioration.The total effective rate in treatment group evaluation was 60%（12/20）.Difference was statistically significant（P 0.05）.Conclusion The curative effect of mifepristone and misoprostol is superior to acetate（dmpa）,and has a good safety and clinical curative effect,can be used as endometrial atypical therapy is one of the preferred solution.
出处
《中国现代药物应用》
2011年第5期25-26,共2页
Chinese Journal of Modern Drug Application
